|
|
|
| Report a case of Prader-Willi syndrome complicated with diabetes mellitus |
| YANG Tao1 GONG qing2 WANG Shidong2 CHUO Wenjing3 LI Jiayue2 WANG Ge2 |
1.The First Clinical Medical College, Beijing University of Chinese Medicine, Beijing 100029,China;
2.Department of Endocrinology of Renal Disease, Dong Zhimen Hospital, Beijing 100700, China;
3.Beijing First Hospital of Traditional Chinese Medicine and Western Medicine, Beijing 100026,China |
|
|
|
|
Abstract This paper reports a case of Prader-Willi syndrome (PWS) with diabetes mellitus, the patient was diagnosed with diabetes in 1996 and was diagnosed with PWS by genetic examination in 2015, the major clinical manifestations are overeating, obesity, and uncontrollable hyperglycemia. In terms of treatment, strict diet control and exercise, the initial hypoglycemic program for oral hypoglycemic drugs combined with insulin, but the efficacy of this treatment is not obvious, and after the use of GPL-1 analogues, the patient's blood glucose levels improved significantly. PWS is a rare syndrome of genetic obesity, due to lack of related gene expression of hypothalamic dysfunction caused by neuroendocrine dysfunction and polyphagia, obesity, poor growth and development of such complicated clinical manifestations. The early diagnosis and timely intervention is important for prognosis of the disease.
|
|
|
|
|
|
[1] Nieholls RD，Saitoh S，Horsthemke B. Imprinting in Prader.Willi and AngeIman syndrome [J]. Trends Genet，1998， 14（5）：194-200.
[2] Whittington JE，Holland AJ，Webb T，et al. Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK health region [J]. Med Genet，2001，38（4）：792-798.
[3] 李洁玲，曹洁. Prader-Willi综合征46例临床分析[J].中国实用儿科杂志，2017（3）：215-219.
[4] Varela MC，Kok F，Setian N，et al. Impact of molecular mechanisms，including deletion size，on Prader-Willi syndrome phenotype：study of 75 patients [J]. Clin Genet，2005，67（1）：47-52.
[5] 朱丽娜，何玺玉，王春枝，等.Prader-Willi综合征的分子遗传学诊断与机制研究[J].山西医科大学学报，2008，39（12）：1064-1067.
[6] 吴晓燕，宋红梅. Prader-Willi综合征的诊断与治疗进展[J].中华儿科杂志，2006，44（9）：666-668.
[7] Schoeller DA，Levitsky LL，BandiniLG，et al. Energy expenditure and body composition in Prader-Willi syndrome [J].Metabolism，1988，37（2）：115-120.
[8] 程向登，梁爽，胡艳艳，等. Prader-Willi综合征患儿下丘脑-垂体-靶腺轴功能及代谢的改变[J].山东大学学报：医学版，2017（3）：107-111.
[9] 洪庆荣，顾绍庆，徐丽琴，等.矮身材患儿176例病因构成分析[J].中国基层医药，2016，23（23）：3526-3530.
[10] 中华医学会儿科学分会内分泌遗传代谢学组，《中华儿科杂志》编辑委员会.中国Prader-Willi综合征诊治专家共识（2015）[J].中华儿科杂志，2015，53（6）：419-424.
[11] Holm VA，Cassidy SB，Butler MG，et al. Prader—Willi syndrome：consensus diagnosis criteria [J].Pediatrics，1993，91（2）：398-402.
[12] Cassidy SB，Schwartz S，Miller JL，et al. Prader-Willi syndrome [J]. Genet Med，2012，14（1）：10-26.
[13] 王薇，魏珉，宋红梅，等.甲基化特异性多重连接探针扩增及甲基化特异性PCR诊断Prader-Willi综合征方法比较[J].协和医学杂志，2014（4）：369-375.
[14] 陈晓红，姚辉.重组人生长激素在Prader-Willi综合征治疗中的应用[J].中华实用儿科临床杂志，2016，31（8）：564-568.
[15] Fintini D，Grugni G，Bocchini S，et al. Disorders of glucose metabolism in prader-willi syndrome：results of a multicenter italian cohort study [J]. Nutr Metab Cardiovasc Dis，2016，26（9）：842-847.
[16] 邹大进.人胰升糖素样肽1类似物利拉鲁肽减轻2型糖尿病患者体重的作用[J].中华内分泌代谢杂志，2011， 27（8）：703-706.
[17] Seetho IW，Jones G，Thomson GA，et al. Treating diabetes mellitus in Prader-Willi syndrome with exenatide [J]. Diabetes Res Clin Pract，2011，92：el-e2.
[18] 董学美，董阳，郭颖杰，等.艾塞那肽治疗合并糖尿病的Prader-Willi综合征一例报告[J].中国糖尿病杂志，2016， 24（5）：465-467.
[19] Lima VP，Emerich DR，Mesquita ML，et al. Nutritional intervention with hypoealoric diet for weight control in children and adolescents with Prader-Willi syndrome [J]. Eat Behav，2016，21：189-192.
[20] 唐军，谷献芳，马友凤.新生儿Prader-Willi综合征误诊分析[J].中国现代药物应用，2014（14）：11-12. |
|
|
|
